Sign Out
The effect of recombinant human erythropoietin can be enhanced by simultaneous administration of another anti-anemia agent. Therefore, administration of iron when treatment with recombinant human erythropoietin does not produce the desired response should be done carefully considering laboratory controls made.
Drugs lowering erythropoiesis may decrease the response to Hemactiv.
Cyclosporine may interact. It is suggested to monitor their blood levels and adjust for any increase in hematocrit.
The administration of trastuzumab 6 mg/kg in patients with metastatic breast cancer along to EPO alpha 40,000 IU/mL did not affect the pharmacokinetics of trastuzumab.
